The company said that all of its CONNEX trials failed to meet expectations showing no impact on patients living with ...

Avacta Therapeutics has reported outcomes from the Phase Ia trial of AVA6000, a drug candidate for solid tumours.

Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.

The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.